Tag results:
hematopoietic stem cells
Cell Therapy News
Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells Improves Immune Cell Engraftment and Therapy-Refractory Chronic GvHD
[Molecular Therapy] Investigators treated three children suffering from severe, therapy-refractory GvHD with polyclonally expanded regulatory T cells generated from the original stem cell donor.
Cell Therapy News
Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients
[Frontiers in Neurology] Investigators found that the proportions of CD19+ IL-10+ cells and CD19+CD24hiCD38hi cell subsets in myasthenia gravis patients were significantly lower than those in healthy controls.
Hematopoiesis News
Hematopoietic Stem and Progenitor Cells Improve Survival from Sepsis by Boosting Immunomodulatory Cells
[eLife] The authors hypothesized that the inflammatory environment of Group A Streptococcus infection drove rapid hematopoietic stem and progenitor cell (HSPC) differentiation and depletion that can be rescued by infusion of donor HSPCs.
Hematopoiesis News
The Contributory Roles of the CXCL12/CXCR4/CXCR7 Axis in Normal and Malignant Hematopoiesis: A Possible Therapeutic Target in Hematologic Malignancies
[European Journal of Pharmacology] The authors discuss how aberrant expression of C-X-C motif chemokine 12 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) and CXCL12/CXCR7 pathways might regulate leukemogenesis and end by outlining the key news of preclinical and clinical investigations in leukemia treatment.
Cell Therapy News
Early Vascular Toxicity after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
[Bone Marrow Transplantation] The authors evaluated the prevalence of key vascular complications and graft-versus-host disease among 122 pediatric patients with an allogeneic hematopoietic stem cell transplantation between 2001 and 2013.
Cancer Stem Cell News
A Novel CD34-Specific T-cell Engager Efficiently Depletes Acute Myeloid Leukemia and Leukemic Stem Cells In Vitro and In Vivo
[Haematologica] Researchers designed a CD34/CD3 bispecific T-cell engager (BiTE) and characterized its anti-leukemia potential in vitro, ex vivo and in vivo.